Effect of BRX‐220 against Peripheral Neuropathy and Insulin Resistance in Diabetic Rat Models

@article{Krthy2002EffectOB,
  title={Effect of BRX‐220 against Peripheral Neuropathy and Insulin Resistance in Diabetic Rat Models},
  author={M{\'a}ria K{\"u}rthy and Tam{\'a}s Mogyor{\'o}si and K{\'a}roly Nagy and Tibor Kukorelli and Andrea Jedn{\'a}kovits and L{\'a}szl{\'o} T{\'a}losi and Katalin B{\'i}r{\'o}},
  journal={Annals of the New York Academy of Sciences},
  year={2002},
  volume={967}
}
Abstract: Bimoclomol (BML), a symptomatic antidiabetic agent, has been developed by Biorex R & D Co. to treat diabetic neuropathy and retinopathy. BRX‐220, an orally active member of the BRX family, has been developed to treat diabetic complications and insulin resistance (IR) as a follow‐up compound. The effect of BRX‐220 on peripheral neuropathy was examined in rats with diabetes (type 1) induced by administration of a β‐cell toxin, streptozotocin (STZ, 45 mg/kg iv). Nerve functions were… 
Assessment of Pharmacological Responses to an Anti-diabetic Drug in a New Obese Type 2 Diabetic Rat Model
TLDR
The SDT fatty rat is useful for the development of novel anti-diabetic agents that show potential to improve glucose metabolic disorders in the liver, and metformin treatment led to maintained good glycemic control and improved neuropathy and pancreatic lesions in female SDT fats.
Targeting Molecular Chaperones in Diabetic Peripheral Neuropathy
TLDR
With the staggering individual, social and economic burden brought about by DPN-associated morbidity and mortality, development of effective treatments that prevent and/or reverse DPN are needed but currently unmet.
Diabetic Peripheral Neuropathy: Should a Chaperone Accompany Our Therapeutic Approach?
TLDR
Combinatorial therapies that target causal mechanisms and enhance endogenous reparative capacity may enhance nerve function and improve regeneration in DPN if they converge to decrease oxidative stress, improve mitochondrial bioenergetics, and increase response to trophic factors.
A Novel Insulin Sensitizer Drug Candidate—BGP-15—Can Prevent Metabolic Side Effects of Atypical Antipsychotics
TLDR
It is found that BGP-15 that does not belong to either conventional insulin sensitizers or oral antidiabetics, is able to counteract insulin resistance and weight gain provoked by antipsychotic agents in rats while rosiglitazone and metformin were not effective in the applied doses.
Reduction in the Dietary VA Status Prevents Type 2 Diabetes and Obesity in Zucker Diabetic Fatty Rats
TLDR
It is concluded that the reduction in the dietary VA status in both BF and HF conditions prevents T2D and obesity in ZDF rats.
Targeting Heat Shock Protein 70 to Improve Oxidative Stress and Mitochondrial Bioenergetics in Diabetic Sensory Neurons
TLDR
Overall, this study shows that the Hsp90 inhibitor KU-596 improved mtBE by decreasing glucose-induced oxidative stress in an Hsp70-dependent manner and was unable to improve MRC.
Bimoclomol and Arimoclomol: HSP-co-Inducers for the Treatment of ProteinMisfolding Disorders, Neuropathy and Neuropathic Pain
TLDR
Arimoclomol has high oral availability and good CNS penetration, without inducing troublesome CNS side effects, and might also be a promising compound for the treatment of diabetic neuropathy and neuropathic pain in (diabetic) neuropathy, due to its neuroprotective and analgesic properties.
HSP72 protects against obesity-induced insulin resistance
TLDR
An essential role is identified for HSP72 in blocking inflammation and preventing insulin resistance in the context of genetic obesity or high-fat feeding and protection against diet- or obesity-induced hyperglycemia, hyperinsulinemia, glucose intolerance, and insulin resistance.
...
...

References

SHOWING 1-9 OF 9 REFERENCES
Thiazolidinediones: a new class of antidiabetic drugs
  • C. Day
  • Medicine
    Diabetic medicine : a journal of the British Diabetic Association
  • 1999
TLDR
Thiazolidinediones have been shown to improve insulin sensitivity in a range of insulin‐resistant states including obesity, impaired glucose tolerance (IGT) and polycystic ovary syndrome (PCOS).
Negative consequences of glycation.
  • M. Brownlee
  • Medicine
    Metabolism: clinical and experimental
  • 2000
Time Courses of Changes in Hepatic and Skeletal Muscle Insulin Action and GLUT4 Protein in Skeletal Muscle After STZ Injection
TLDR
The data indicate that there is a temporal hierarchy in the development of insulin resistance in STZ-induced diabetes, andulin resistance in skeletal muscle appears last (between days 3 and 7 after STZ administration), and the resistance in muscle cannot be fully accounted for by reduced GLUT4 expression.
Bimoclomol improves early electrophysiological signs of retinopathy in diabetic rats
TLDR
Treatment of streptozotocin-diabetic rats for 1 or 2 months with the heat-shock protein coinducer bimoclomol prevented and corrected the abnormal increase in latency and reduction of amplitude of ERG and VEP waves both in acute and chronic experiments.
Obesity and insulin resistance.
  • B. Kahn, J. Flier
  • Medicine, Biology
    The Journal of clinical investigation
  • 2000
TLDR
Recent progress in understanding of the adipo-insulin axis is reviewed, areas of controversy or uncertainty are highlighted, and approaches to clarifying the unresolved issues are suggested.
Glycation Products and the Pathogenesis of Diabetic Complications
TLDR
Data suggest that aminoguanidine and other AGE inhibitors have a potential therapeutic role in the treatment of diabetic patients and the persistence of accumulated AGEs during periods of normal glucose homeostasis may explain the phenomenon of hyperglycemic memory.
Bimoclomol: A nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects
TLDR
A novel cytoprotective hydroxylamine derivative, [2-hydroxy-3-(1-piperidinyl) propoxy]-3-pyridinecarboximidoil-chloride maleate, Bimoclomol15, facilitates the formation of chaperone molecules in eukaryotic cells by inducing or amplifying expression of heat-shock genes.